These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1829 related articles for article (PubMed ID: 22786462)

  • 21. Transdermal buprenorphine, opioid rotation to sublingual buprenorphine, and the avoidance of precipitated withdrawal: a review of the literature and demonstration in three chronic pain patients treated with butrans.
    Kornfeld H; Reetz H
    Am J Ther; 2015; 22(3):199-205. PubMed ID: 23846520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal buprenorphine controls central neuropathic pain.
    Weiner M; Sarantopoulos C; Gordon E
    J Opioid Manag; 2012; 8(6):414-5. PubMed ID: 23264319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
    Miner JR; Moore J; Gray RO; Skinner L; Biros MH
    Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Office-based opioid dependence treatment.
    Colson J; Helm S; Silverman SM
    Pain Physician; 2012 Jul; 15(3 Suppl):ES231-6. PubMed ID: 22786460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Buprenorphine: new tricks with an old molecule for pain management.
    Heit HA; Gourlay DL
    Clin J Pain; 2008 Feb; 24(2):93-7. PubMed ID: 18209513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.
    Pade PA; Cardon KE; Hoffman RM; Geppert CM
    J Subst Abuse Treat; 2012 Dec; 43(4):446-50. PubMed ID: 22980449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
    Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
    J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
    Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
    Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of dosing frequency of sustained-release opioid preparations in patients with chronic nonmalignant pain.
    Gallagher RM; Welz-Bosna M; Gammaitoni A
    Pain Med; 2007; 8(1):71-4. PubMed ID: 17244106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Continuation of Buprenorphine to Facilitate Postoperative Pain Management for Patients on Buprenorphine Opioid Agonist Therapy.
    Mehta D; Thomas V; Johnson J; Scott B; Cortina S; Berger L
    Pain Physician; 2020 Mar; 23(2):E163-E174. PubMed ID: 32214293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion of CII Opioid Medications to Buprenorphine in the Chronic Pain Population - Insights and Clinical Pearls.
    Zimmerman A
    J Opioid Manag; 2024; 20(4):B11. PubMed ID: 39321065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain.
    Manchikanti L; Manchikanti KN; Pampati V; Cash KA
    Pain Physician; 2009; 12(1):259-67. PubMed ID: 19165308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
    Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
    JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S; Peters J; Rock A; Pavliv L
    Clin Ther; 2009 Sep; 31(9):1922-35. PubMed ID: 19843482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 92.